

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 19th June 2019
Ein Cyf / Our Ref: 19-E-043

☎ 01639 683312

☎ 01639 648363

🖱 FOIA.Requests@wales.nhs.uk

Corporate Administration
Headquarters
1 Talbot Gateway
Baglan
Port Talbot, SA12 7BR

[REDACTED]

[REDACTED]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 29th May 2019. Your request sought information relating to treatments.

Please note that from 1st April 2019 responsibility for providing healthcare services for people in the Bridgend County Borough Council area transferred from Abertawe Bro Morgannwg University Health Board to Cwm Taf Morgannwg University Health Board. In light of this change to ABMU's responsibilities, the organisation's name has changed to Swansea Bay University Health Board. Therefore this response will include Bridgend data prior to April 2019.

Could you please provide me with following numbers of patients treated in the last 12 months (latest 12 months possible) with the following drugs for either Rheumatology, Dermatology and Gastroenterology departments:

The following information is for the period June 2019 to May 2019:

Treatment	Total	Rheumatology	Dermatology	Gastroenterology
Abatacept (Orencia)	96	96	0	0
Adalimumab biosimilar (Amgevita)	43	0	27	16
Adalimumab biosimilar (Hulio)	0	0	0	0
Adalimumab (Humira)	551	366	98	87



Adalimumab biosimilar (Hyrimoz)	0	0	0	0
Adalimumab bioisimilar (Imraldi)	327	327	0	0
Apremilast (Otezla)	100	28	72	0
Baricitinib (Olumiant)	141	141	0	0
Brodalumab (Kyntheum)	19	0	19	0
Certolizumab (Cimzia)	58	57	0	<5
Dimethyl Fumarate (Skilarence)	7	0	7	0
Etanercept (Enbrel)	153	152	<5	0
Etanercept Biosimilar (Benepali)	494	469	25	0
Etanercept Biosimilar (Erelzi)	0	0	0	0
Golimuab (Simponi)	44	43	0	<5
Guselkumab (Tremfya)	22	0	22	0
Infliximab (Flixabi)	0	0	0	0
Infliximab (Inflectra)	229*	14*	13	201
Infliximab (Remicade)	31	<5	<5	28
Infliximab (Remsima)	0	0	0	0
Ixekizumab (Taltz)	13	0	13	0
Rituximab (Mabthera)	<5	<5	0	0
Rituximab Biosimilar (Rixathon)	0	0	0	0
Rituximab Biosimilar (Truxima)	<5*	<5*	0	0
Sarilumab (Kevzara)	<5	<5	0	0
Secukinumab (Cosentyx)	110	70	40	0



Tildrakizumab (Ilumetri)	0	0	0	0
Tocilizumab (Ro Actemra)	102*	102	0	0
Tofacitinib (Xeljanz)	37	37	0	0
Ustekinumab (Stelara)	129	13	93	23
Vedolizumab (Entyvio)	66	0	0	66

*These medications are issued as stock items to ward areas and therefore we are not able to quantify exact patient numbers for these medications, therefore the total patient quantity is likely to be more than that stated.

Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at FOIA.Requests@wales.nhs.uk.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via FOIA.Requests@wales.nhs.uk.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



On behalf of

Pam Wenger

Director of Corporate Governance

